2315 — Biocytogen Pharmaceuticals Beijing Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapHigh Flyer

Market Cap
HK$12.15bn
Enterprise Value
HK$12.33bn
Revenue
CNY980.45m

Annual income statement for Biocytogen Pharmaceuticals Beijing Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	254	355	534	717	980
Cost of Revenue
Gross Profit	167	247	392	506	762
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	612	860	1,064	987	816
Operating Profit	-358	-506	-530	-270	164
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-477	-546	-601	-380	42.9
Provision for Income Taxes
Net Income After Taxes	-477	-546	-602	-383	33.5
Minority Interest
Net Income Before Extraordinary Items
Net Income	-428	-546	-602	-383	33.5
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-428	-546	-602	-383	33.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.12	-1.4	-1.63	-0.988	0.056